Table 2 Clinical correlates of the progression of diastolic class over follow-up
| Stable (n = 95) | Deteriorated (n = 50) | Improved (n = 39) | ||||
| No (%) | No (%) | p vs stable | No (%) | p vs stable | p vs com | |
| Age (years) (SD) | 62.0 (12.0) | 61.6 (12.5) | 0.88 | 62.1 (13.8) | 0.96 | |
| Male gender | 65 (68.4) | 32 (64) | 0.59 | 24 (61.5) | 0.70 | 0.39 |
| Endpoints | ||||||
| Total mortality | 17 (17.9) | 9 (18) | 0.99 | 7 (17.9) | 0.99 | 0.99 |
| Heart failure or atrial fibrillation | 10 (10.5) | 7 (14) | 0.48 | 6 (15.4) | 0.43 | 0.54 |
| Co-morbidity | ||||||
| Cancer | 4 (4.2) | 1 (2) | 0.49 | 3 (7.7) | 0.41 | 0.25 |
| Coronary artery disease | 43 (45.3) | 22 (44) | 0.88 | 15 (38.5) | 0.47 | 0.48 |
| Risk factors | ||||||
| Diabetes mellitus | 28 (29.5) | 16 (32) | 0.75 | 12 (30.8) | 0.53 | 0.96 |
| Hypertension | 81 (32.6) | 42 (84) | 0.84 | 27 (69.2) | 0.03 | 0.03 |
| Hyperlipidaemia | 64 (67.4) | 37 (74) | 0.41 | 22 (56.4) | 0.23 | 0.12 |
| Family history | 17 (17.9) | 12 (24) | 0.38 | 8 (20.5) | 0.72 | 0.94 |
| Smoking | 60 (63.2) | 24 (48) | 0.08 | 22 (56.4) | 0.47 | 0.87 |
| Body mass index | 63 (71.6) | 27 (61.4) | 0.74 | 27 (69.2) | 0.16 | 0.98 |
| Medications | ||||||
| ACE/ARB/aldo antagonist | 94 (98.9) | 50 (100) | 0.47 | 31 (79.5) | 0.00 | 0.00 |
| β-blocker | 59 (62.1) | 30 (60) | 0.81 | 19 (48.7) | 0.15 | 0.15 |
| Calcium channel blocker | 54 (56.8) | 26 (52) | 0.58 | 20 (51.3) | 0.56 | 0.67 |
| Diuretic | 53 (55.8) | 29 58) | 0.80 | 17 (43.6) | 0.20 | 0.15 |
| Nitrate | 32 (33.7) | 16 (32) | 0.84 | 13 (33.3) | 0.97 | 0.98 |
| Statin | 59 (62.1) | 30 (60) | 0.81 | 16 (41.0) | 0.03 | 0.02 |
-
ACE, angiotensin converting enzyme inhibitor; aldo, aldosterone; ARB, angiotensin receptor blocker.
